{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-24-000032","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2024-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.759268+00:00","generated_at":"2026-06-05T23:06:44.315827+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Summit Therapeutics reports Q4 2023 GAAP net loss $36.6M; cash runway extended to Q1 2025 via $100M CEO note amendment","bullets":["GAAP net loss Q4 2023 $36.6M ($0.05/sh) vs $19.3M ($0.07/sh) a year ago; full-year loss $614.9M primarily from $500M ivonescimab licensing fee.","Cash and equivalents, restricted cash, and short-term investments $186.2M at Dec 31, 2023, down from $648.6M at Dec 31, 2022.","Extended cash runway guidance to Q1 2025 from Q3 2024 after amending $100M CEO note to April 1, 2025 maturity with interest rate >12%.","Actively enrolling two Phase III trials (HARMONi and HARMONi-3) for ivonescimab in NSCLC; HARMONi enrollment completion expected H2 2024.","Updated Phase II data: 24-month OS rate 64.8% in 1L squamous NSCLC; median OS 22.5 months in 2L+ EGFR-mutant NSCLC."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-24-000032","json":"https://secwatch.observer/filing/0001599298-24-000032.json","markdown":"https://secwatch.observer/filing/0001599298-24-000032.md","text":"https://secwatch.observer/filing/0001599298-24-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929824000032/0001599298-24-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929824000032/smmt-20240220.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T23:06:44.315827+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cd5188a8efe848d98315388c100320fc27a98ded","claim":"Summit Therapeutics Inc. updated its the fourth quarter and year ended December 31, 2023 guidance (reaffirmed).","evidence_excerpt":"On February 20, 2024, Summit Therapeutics Inc. (the “Company”) issued a press release announcing its financial results and operational progress for the fourth quarter and full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1599298/000159929824000032/0001599298-24-000032-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}